Literature DB >> 21181484

X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins.

L Messori1, A Balerna, I Ascone, C Castellano, C Gabbiani, A Casini, C Marchioni, G Jaouen, A Congiu Castellano.   

Abstract

Gold metallodrugs form a class of promising antiproliferative agents showing a high propensity to react with proteins. We exploit here X-ray absorption spectroscopy (XAS) methods [both X-ray absorption near-edge spectroscopy (XANES) and extended X-ray absorption fine structure (EXAFS)] to gain insight into the nature of the adducts formed between three representative gold(I, III) metallodrugs (i.e., auranofin, [Au(2,2'-bipyridine)(OH)(2)](PF(6)), Aubipy, and dinuclear [Au(2)(6,6'-dimethyl-2,2'-bipyridine)(2)(μ-O)(2)](PF(6))(2), Auoxo6) and two major plasma proteins, namely, bovine serum albumin (BSA) and human serum apotransferrin (apoTf). The following metallodrug-protein systems were investigated in depth: auranofin/apoTf, Aubipy/BSA, and Auoxo6/apoTf. XANES spectra revealed that auranofin, upon protein binding, conserves its gold(I) oxidation state. Protein binding most probably takes place through release of the thiosugar ligand and its subsequent replacement by a thiol (or a thioether) from the protein. This hypothesis is independently supported by EXAFS results. In contrast, the reactions of Aubipy with serum albumin and of Auoxo6 with serum apoTf invariantly result in gold(III) to gold(I) reduction. Gold(III) reduction, clearly documented by XANES, is accompanied, in both cases, by release of the bipyridyl ligands; for Auoxo6 cleavage of the gold-gold dioxo bridge is also observed. Gold(III) reduction leads to formation of protein-bound gold(I) species, with deeply modified metal coordination environments, as evidenced by EXAFS. In these adducts, the gold(I) centers are probably anchored to the protein through nitrogen donors. In general, these two XAS methods, i.e., XANES and EXAFS, used here jointly, allowed us to gain independent structural information on metallodrug/protein systems; detailed insight into the gold oxidation state and the local environment of protein-bound metal atoms was achieved in the various cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181484     DOI: 10.1007/s00775-010-0748-5

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  29 in total

1.  XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents.

Authors:  Matthew D Hall; Garry J Foran; Mei Zhang; Philip J Beale; Trevor W Hambley
Journal:  J Am Chem Soc       Date:  2003-06-25       Impact factor: 15.419

2.  Imaging metals in proteins by combining electrophoresis with rapid x-ray fluorescence mapping.

Authors:  Lydia Finney; Yasmin Chishti; Tripti Khare; Carol Giometti; Aviva Levina; Peter A Lay; Stefan Vogt
Journal:  ACS Chem Biol       Date:  2010-06-18       Impact factor: 5.100

Review 3.  Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

Authors:  Andrei R Timerbaev; Christian G Hartinger; Svetlana S Aleksenko; Bernhard K Keppler
Journal:  Chem Rev       Date:  2006-06       Impact factor: 60.622

4.  A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2]- to human serum albumin.

Authors:  Jihan Talib; Jennifer L Beck; Stephen F Ralph
Journal:  J Biol Inorg Chem       Date:  2006-05-12       Impact factor: 3.358

Review 5.  Imaging and speciation of trace elements in biological environment.

Authors:  R Lobinski; C Moulin; R Ortega
Journal:  Biochimie       Date:  2006-10-16       Impact factor: 4.079

Review 6.  Recent developments in ruthenium anticancer drugs.

Authors:  Aviva Levina; Anannya Mitra; Peter A Lay
Journal:  Metallomics       Date:  2009-08-13       Impact factor: 4.526

7.  Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties.

Authors:  Giordana Marcon; Stefania Carotti; Marcella Coronnello; Luigi Messori; Enrico Mini; Pierluigi Orioli; Teresita Mazzei; Maria Agostina Cinellu; Giovanni Minghetti
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

8.  Formation and characterization of aurothioneins: Au,Zn,Cd-thionein, Au,Cd-thionein, and (thiomalato-Au)chi-thionein.

Authors:  J E Laib; C F Shaw; D H Petering; M K Eidsness; R C Elder; J S Garvey
Journal:  Biochemistry       Date:  1985-04-09       Impact factor: 3.162

9.  X-ray absorption near-edge spectroscopy of transferrins: a theoretical and experimental probe of the metal site local structure.

Authors:  F Boffi; I Ascone; S Della Longa; M Girasole; G Yalovega; A V Soldatov; A Varoli-Piazza; A Congiu Castellano
Journal:  Eur Biophys J       Date:  2003-02-28       Impact factor: 1.733

10.  Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study.

Authors:  Angela Casini; Gerhard Kelter; Chiara Gabbiani; Maria Agostina Cinellu; Giovanni Minghetti; Dolores Fregona; Heinz-Herbert Fiebig; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2009-06-20       Impact factor: 3.358

View more
  2 in total

1.  Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy(c.).

Authors:  Luigi Messori; Maria Agostina Cinellu; Antonello Merlino
Journal:  ACS Med Chem Lett       Date:  2014-07-31       Impact factor: 4.345

2.  Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme.

Authors:  Chiara Gabbiani; Lara Massai; Federica Scaletti; Elena Michelucci; Laura Maiore; Maria Agostina Cinellu; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2012-11-07       Impact factor: 3.358

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.